↓ Skip to main content

Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults

Overview of attention for article published in Journal of Epidemiology & Community Health, January 2018
Altmetric Badge

Mentioned by

blogs
1 blog
twitter
6 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults
Published in
Journal of Epidemiology & Community Health, January 2018
DOI 10.1136/jech-2017-209864
Pubmed ID
Authors

Mark Canney, Donal J Sexton, Neil O’Leary, Martin Healy, Rose Anne Kenny, Mark A Little, Conall M O’Seaghdha

Abstract

Cystatin C has been proposed as a confirmatory test of chronic kidney disease (CKD). This is most applicable to older individuals with CKD, the majority of whom have a creatinine-based estimated glomerular filtration rate (eGFR) of 45-59 mL/min/1.73 m2 (CKD stage 3a). We sought to examine the utility of cystatin C as a confirmatory test of CKD across the age range in the general population of older adults. Cross-sectional analysis of 5386 participants from The Irish Longitudinal Study on Ageing, a cluster-sampled national cohort of community-dwelling adults aged ≥50 years. Cystatin C and creatinine were measured simultaneously using standardised assays. Using generalised additive models, we modelled the distributions of creatinine and cystatin C per year of age from four distributional parameters: location, dispersion, skewness, kurtosis. Among participants with CKD stage 3a, we estimated the predicted probability of cystatin C eGFR <60 mL/min/1.73 m2 ('confirmed CKD') as a function of age. Median age was 62 years, 53% were female and median cystatin C eGFR was 80 mL/min/1.73 m2. We observed progressive variability in cystatin C with increasing age. Compared with creatinine, cystatin C levels rose sharply beyond the age of 65. Among participants with CKD stage 3a (n=463), the predicted probability of 'confirmed CKD' increased steadily with age, from 15% at age 50 to 80% at age 80. The clinical utility of cystatin C may be maximised in middle-aged individuals, in whom the distribution of cystatin C is less variable than older adults, and the pretest probability of confirming CKD is lower.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 33%
Student > Bachelor 2 13%
Student > Ph. D. Student 2 13%
Student > Doctoral Student 1 7%
Unspecified 1 7%
Other 1 7%
Unknown 3 20%
Readers by discipline Count As %
Medicine and Dentistry 5 33%
Materials Science 2 13%
Unspecified 1 7%
Psychology 1 7%
Biochemistry, Genetics and Molecular Biology 1 7%
Other 2 13%
Unknown 3 20%